Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: Pfizer B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (ALL)

 


Pfizer B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (ALL)


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of investigational drug inotuzumab ozogamicin which will be administered by IV.

IRB Protocol #

13-0027

Trial Status

Archived

Principle Investigator

DAN POLLYEA

Sponsor

Pfizer

Contact

EMILY DENONCOURT at (303)748-0566 or EMILY.DENONCOURT@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period will last up to 6 months. Approximately 28 days after your last dose of study drug, you will have an End of Treatment visit. The follow up period will last two years, which will include routine clinic visits. // Eligibility includes but is not limited to 18 years or older with relapsed or refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL).Eligibility includes but is not limited to 18 years or older with relapsed or refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL).